Phase III intermittent MAB vs continuous MAB

F.M.C. Da Silva, F.C. Da Silva, Aldo V. Bono, Maurizio Brausi, Peter Whelan, Anton Marques Queimadelos, J. Portillo, C. Robertson, Ziya Kirkali, South European Uroncological Group

Research output: Contribution to journalArticle

Abstract

Patients with locally advanced or metastatic prostate cancer cannot be cured with any of the therapeutic tools available today. After an initial induction treatment of three months, with CPA 200 mg for two week's and then monthly depot injections of LHRH analogue (decaptyl) plus 200 mg of CPA daily in 766 patients with locally advanced or metastatic prostate cancer, 626 patients whose PSA decreased below 4 or to 80% below their initial value, were randomised to intermittent or continuous therapy. Among the 314 patients on Intermittent therapy, 50% have been off therapy for at least 52 weeks following the initial LHRH therapy, 29% have been off therapy for over 36 months. For the 197 patients whose PSA went down to 2 ng/ml, the median time off therapy was 74 weeks. When these patients returned to therapy they had a median of 14 weeks of treatment, followed by a second period off therapy, median 70 weeks. Patients with PSA < 2 ng/ml have spent a median of 82% of their time receiving no therapy.After a median follow up of 51 months, 321 patients have died: 162 in the Intermittent arm compared to 159 in the Continuous arm (HR = 1.03 [95% confidence interval 0.83, 1.28; p = 0.79]). Estimated survival at 5 years was 53.8% in the Intermittent Group and 51.0% in the Continuous Group.Subjective or Objective progression was noted in 224 patients, 113 on the intermittent arm and 111 on the continuous arm with a hazard ratio of 1.09 (95% CI 0.84, 1.42), p=0.52. The main differences in quality of life between the two arms of the study were confined to sexual function. Sexual activity was significantly greater (p<0.01) in the intermittent arm with 41% of men reporting sexual activity at 9 months, 40% at 15 months and 35% at 21 months.The most commonly reported side effects were hot flushes, were more frequently among those on Continuous Therapy, 30% of continuous patients compared to 20% of intermittent patients, p < 0.01. There is no evidence that Intermittent therapy leads to a significantly elevated hazard of dying (p = 0.79) or to a greater subjective or objective progression (p = 0.52) and with less impact on quality of live and less medication, patients with PSA < 2 ng/ml on randomisation have spent a median of 82% of their time receiving no therapy. We think that intermittent therapy is an option to use in regular clinic.
LanguageEnglish
Pages4513-4513
Number of pages0
JournalJournal of Clinical Oncology
Volume24
Issue numberSupplement 18
Publication statusPublished - 20 Jun 2006

Fingerprint

Therapeutics
Gonadotropin-Releasing Hormone
Sexual Behavior
Prostatic Neoplasms
Random Allocation
Quality of Life
Confidence Intervals
Injections
Survival

Keywords

  • oncology
  • metastatic prostate cancer
  • cancer
  • therapy

Cite this

Da Silva, F. M. C., Da Silva, F. C., Bono, A. V., Brausi, M., Whelan, P., Queimadelos, A. M., ... South European Uroncological Group (2006). Phase III intermittent MAB vs continuous MAB. Journal of Clinical Oncology, 24(Supplement 18), 4513-4513.
Da Silva, F.M.C. ; Da Silva, F.C. ; Bono, Aldo V. ; Brausi, Maurizio ; Whelan, Peter ; Queimadelos, Anton Marques ; Portillo, J. ; Robertson, C. ; Kirkali, Ziya ; South European Uroncological Group. / Phase III intermittent MAB vs continuous MAB. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. Supplement 18. pp. 4513-4513.
@article{1d547e22ee8b4d988476772ec41283dd,
title = "Phase III intermittent MAB vs continuous MAB",
abstract = "Patients with locally advanced or metastatic prostate cancer cannot be cured with any of the therapeutic tools available today. After an initial induction treatment of three months, with CPA 200 mg for two week's and then monthly depot injections of LHRH analogue (decaptyl) plus 200 mg of CPA daily in 766 patients with locally advanced or metastatic prostate cancer, 626 patients whose PSA decreased below 4 or to 80{\%} below their initial value, were randomised to intermittent or continuous therapy. Among the 314 patients on Intermittent therapy, 50{\%} have been off therapy for at least 52 weeks following the initial LHRH therapy, 29{\%} have been off therapy for over 36 months. For the 197 patients whose PSA went down to 2 ng/ml, the median time off therapy was 74 weeks. When these patients returned to therapy they had a median of 14 weeks of treatment, followed by a second period off therapy, median 70 weeks. Patients with PSA < 2 ng/ml have spent a median of 82{\%} of their time receiving no therapy.After a median follow up of 51 months, 321 patients have died: 162 in the Intermittent arm compared to 159 in the Continuous arm (HR = 1.03 [95{\%} confidence interval 0.83, 1.28; p = 0.79]). Estimated survival at 5 years was 53.8{\%} in the Intermittent Group and 51.0{\%} in the Continuous Group.Subjective or Objective progression was noted in 224 patients, 113 on the intermittent arm and 111 on the continuous arm with a hazard ratio of 1.09 (95{\%} CI 0.84, 1.42), p=0.52. The main differences in quality of life between the two arms of the study were confined to sexual function. Sexual activity was significantly greater (p<0.01) in the intermittent arm with 41{\%} of men reporting sexual activity at 9 months, 40{\%} at 15 months and 35{\%} at 21 months.The most commonly reported side effects were hot flushes, were more frequently among those on Continuous Therapy, 30{\%} of continuous patients compared to 20{\%} of intermittent patients, p < 0.01. There is no evidence that Intermittent therapy leads to a significantly elevated hazard of dying (p = 0.79) or to a greater subjective or objective progression (p = 0.52) and with less impact on quality of live and less medication, patients with PSA < 2 ng/ml on randomisation have spent a median of 82{\%} of their time receiving no therapy. We think that intermittent therapy is an option to use in regular clinic.",
keywords = "oncology, metastatic prostate cancer, cancer, therapy",
author = "{Da Silva}, F.M.C. and {Da Silva}, F.C. and Bono, {Aldo V.} and Maurizio Brausi and Peter Whelan and Queimadelos, {Anton Marques} and J. Portillo and C. Robertson and Ziya Kirkali and {South European Uroncological Group}",
note = "Also presented at the 2006 ASCO Annual Meeting.",
year = "2006",
month = "6",
day = "20",
language = "English",
volume = "24",
pages = "4513--4513",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
number = "Supplement 18",

}

Da Silva, FMC, Da Silva, FC, Bono, AV, Brausi, M, Whelan, P, Queimadelos, AM, Portillo, J, Robertson, C, Kirkali, Z & South European Uroncological Group 2006, 'Phase III intermittent MAB vs continuous MAB' Journal of Clinical Oncology, vol. 24, no. Supplement 18, pp. 4513-4513.

Phase III intermittent MAB vs continuous MAB. / Da Silva, F.M.C.; Da Silva, F.C.; Bono, Aldo V.; Brausi, Maurizio; Whelan, Peter; Queimadelos, Anton Marques; Portillo, J.; Robertson, C.; Kirkali, Ziya; South European Uroncological Group.

In: Journal of Clinical Oncology, Vol. 24, No. Supplement 18, 20.06.2006, p. 4513-4513.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase III intermittent MAB vs continuous MAB

AU - Da Silva, F.M.C.

AU - Da Silva, F.C.

AU - Bono, Aldo V.

AU - Brausi, Maurizio

AU - Whelan, Peter

AU - Queimadelos, Anton Marques

AU - Portillo, J.

AU - Robertson, C.

AU - Kirkali, Ziya

AU - South European Uroncological Group

N1 - Also presented at the 2006 ASCO Annual Meeting.

PY - 2006/6/20

Y1 - 2006/6/20

N2 - Patients with locally advanced or metastatic prostate cancer cannot be cured with any of the therapeutic tools available today. After an initial induction treatment of three months, with CPA 200 mg for two week's and then monthly depot injections of LHRH analogue (decaptyl) plus 200 mg of CPA daily in 766 patients with locally advanced or metastatic prostate cancer, 626 patients whose PSA decreased below 4 or to 80% below their initial value, were randomised to intermittent or continuous therapy. Among the 314 patients on Intermittent therapy, 50% have been off therapy for at least 52 weeks following the initial LHRH therapy, 29% have been off therapy for over 36 months. For the 197 patients whose PSA went down to 2 ng/ml, the median time off therapy was 74 weeks. When these patients returned to therapy they had a median of 14 weeks of treatment, followed by a second period off therapy, median 70 weeks. Patients with PSA < 2 ng/ml have spent a median of 82% of their time receiving no therapy.After a median follow up of 51 months, 321 patients have died: 162 in the Intermittent arm compared to 159 in the Continuous arm (HR = 1.03 [95% confidence interval 0.83, 1.28; p = 0.79]). Estimated survival at 5 years was 53.8% in the Intermittent Group and 51.0% in the Continuous Group.Subjective or Objective progression was noted in 224 patients, 113 on the intermittent arm and 111 on the continuous arm with a hazard ratio of 1.09 (95% CI 0.84, 1.42), p=0.52. The main differences in quality of life between the two arms of the study were confined to sexual function. Sexual activity was significantly greater (p<0.01) in the intermittent arm with 41% of men reporting sexual activity at 9 months, 40% at 15 months and 35% at 21 months.The most commonly reported side effects were hot flushes, were more frequently among those on Continuous Therapy, 30% of continuous patients compared to 20% of intermittent patients, p < 0.01. There is no evidence that Intermittent therapy leads to a significantly elevated hazard of dying (p = 0.79) or to a greater subjective or objective progression (p = 0.52) and with less impact on quality of live and less medication, patients with PSA < 2 ng/ml on randomisation have spent a median of 82% of their time receiving no therapy. We think that intermittent therapy is an option to use in regular clinic.

AB - Patients with locally advanced or metastatic prostate cancer cannot be cured with any of the therapeutic tools available today. After an initial induction treatment of three months, with CPA 200 mg for two week's and then monthly depot injections of LHRH analogue (decaptyl) plus 200 mg of CPA daily in 766 patients with locally advanced or metastatic prostate cancer, 626 patients whose PSA decreased below 4 or to 80% below their initial value, were randomised to intermittent or continuous therapy. Among the 314 patients on Intermittent therapy, 50% have been off therapy for at least 52 weeks following the initial LHRH therapy, 29% have been off therapy for over 36 months. For the 197 patients whose PSA went down to 2 ng/ml, the median time off therapy was 74 weeks. When these patients returned to therapy they had a median of 14 weeks of treatment, followed by a second period off therapy, median 70 weeks. Patients with PSA < 2 ng/ml have spent a median of 82% of their time receiving no therapy.After a median follow up of 51 months, 321 patients have died: 162 in the Intermittent arm compared to 159 in the Continuous arm (HR = 1.03 [95% confidence interval 0.83, 1.28; p = 0.79]). Estimated survival at 5 years was 53.8% in the Intermittent Group and 51.0% in the Continuous Group.Subjective or Objective progression was noted in 224 patients, 113 on the intermittent arm and 111 on the continuous arm with a hazard ratio of 1.09 (95% CI 0.84, 1.42), p=0.52. The main differences in quality of life between the two arms of the study were confined to sexual function. Sexual activity was significantly greater (p<0.01) in the intermittent arm with 41% of men reporting sexual activity at 9 months, 40% at 15 months and 35% at 21 months.The most commonly reported side effects were hot flushes, were more frequently among those on Continuous Therapy, 30% of continuous patients compared to 20% of intermittent patients, p < 0.01. There is no evidence that Intermittent therapy leads to a significantly elevated hazard of dying (p = 0.79) or to a greater subjective or objective progression (p = 0.52) and with less impact on quality of live and less medication, patients with PSA < 2 ng/ml on randomisation have spent a median of 82% of their time receiving no therapy. We think that intermittent therapy is an option to use in regular clinic.

KW - oncology

KW - metastatic prostate cancer

KW - cancer

KW - therapy

UR - http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/4513

M3 - Article

VL - 24

SP - 4513

EP - 4513

JO - Journal of Clinical Oncology

T2 - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - Supplement 18

ER -

Da Silva FMC, Da Silva FC, Bono AV, Brausi M, Whelan P, Queimadelos AM et al. Phase III intermittent MAB vs continuous MAB. Journal of Clinical Oncology. 2006 Jun 20;24(Supplement 18):4513-4513.